Dolutegravir
Overview
Primary Characterstics
Doxacurium is also known as Isoquinolinium dichloride. Doxacurium Chloride is the derivative of DoxacuriumDoxacurium is also known as Isoquinolinium dichloride. Doxacurium Chloride is the derivative of Doxacurium It is of Synthetic origin and belongs to Isoquinolinium. It belongs to Anticholinesterase agent pharmacological group on the basis of mechanism of action and also classified in Neuromuscular Blocking Agent, Nondepolarizing pharmacological group.The Molecular Weight of Doxacurium is 1106.14.
Indications
Back to top
Pharmacokinetics
Back to top
Contraindications
Back to top
Back to top
Side Effects
Back to top
Dosage
Dolutegravir's dosage details are as follows:
| Dose
|
Single Dose
|
Frequency
|
Route
|
Instructions
|
Adult Dosage
|
| 0 to 50 mg | 25 (25) | As recommended. | PO | Patients infected with HIV-1 without suspected resistance to the integrase class |
| 50 mg | 50 (50) | As recommended. | PO | patient infected with HIV-1 without suspected resistance to the integrase classwhen co-administered with some medicines (e.g. efavirenz, nevirapine, tipranavir/ritonavir, or rifampicin) i |
| 50 mg | 50 (50) | As recommended. | PO | Patients infected with HIV-1 with resistance to the integrase class |
Paedriatic Dosage (20kg)
|
| 0 to 50 mg | 25 (25) | As recommended. | PO | pediatric patients aged 12 years and older and weighing at least 40 kg |
Neonatal Dosage (3kg)
|
| No data regarding the neonatal dosage details of Dolutegravir is available. |
High Risk Groups
Drug should not be given to patients suffering from Kidney dysfunction, and patients suffering from Liver Malfunction.
If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Back to top
Warning / Precautions
Should be administered in carefully adjusted dosage by or under the supervision of experienced clinicians who are familiar with the drug's actions and the possible complications of its use. The drug should not be administered unless facilities for intubation, artificial respiration, oxygen therapy, and an antagonist are within immediate reach. It is recommended that clinicians administering long-acting neuromuscular blocking agents employ a peripheral nerve stimulator to monitor drug response, need for additional relaxants, and adequacy of spontaneous recovery or antagonism.
Back to top
Storage Conditions
Back to top
Interference in Pathology
Back to top
Brands / Trade Names of
Dolutegravir
No Brands Available.
Back to top
Previous Drug Generic - Next Drug Generic